
Novo’s blockbuster drugs could pull it into buzzier areas of healthcare, chief executive Mike Doustdar said, as the Ozempic maker seeks to lessen its reliance on obesity and diabetes.
Source link
Novo Nordisk Looks Beyond Weight Loss to Longevity and Aesthetics